Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Rating Raised to Hold at Wall Street Zen

Posted by Brenda Bartman on Nov 8th, 2026

Wall Street Zen upgraded shares of Quoin Pharmaceuticals (NASDAQ:QNRX – Free Report) from a sell rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a report on Friday, October 16th. BTIG Research initiated coverage on shares of Quoin Pharmaceuticals in a research report on Monday, October 12th. They set a “buy” rating and a $14.00 price target for the company. Lake Street Capital initiated coverage on shares of Quoin Pharmaceuticals in a research report on Wednesday, September 23rd. They issued a “buy” rating and a $20.00 target price for the company. Finally, Canaccord Genuity Group began coverage on shares of Quoin Pharmaceuticals in a research note on Monday, October 19th. They issued a “buy” rating and a $18.00 price target on the stock. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Quoin Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $17.33.

Get Our Latest Analysis on Quoin Pharmaceuticals

Quoin Pharmaceuticals Stock Down 3.2%

Shares of QNRX stock opened at $3.73 on Friday. The company has a market cap of $17.88 million, a P/E ratio of -0.19 and a beta of 1.71. The business has a 50 day moving average of $5.29 and a two-hundred day moving average of $5.93. Quoin Pharmaceuticals has a 52 week low of $3.25 and a 52 week high of $23.50.

Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.97) EPS for the quarter, topping analysts’ consensus estimates of ($1.52) by $0.55. Analysts expect that Quoin Pharmaceuticals will post -7.45 EPS for the current fiscal year.

Insider Transactions at Quoin Pharmaceuticals

In other Quoin Pharmaceuticals news, COO Denise P. Carter acquired 20,490 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The shares were purchased at an average price of $4.88 per share, with a total value of $99,991.20. Following the completion of the transaction, the chief operating officer owned 37,709 shares in the company, valued at $184,019.92. The trade was a 119.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Sally Lawlor bought 10,244 shares of Quoin Pharmaceuticals stock in a transaction on Monday, August 31st. The stock was acquired at an average price of $4.88 per share, with a total value of $49,990.72. Following the completion of the purchase, the chief financial officer directly owned 10,684 shares of the company’s stock, valued at approximately $52,137.92. The trade was a 2,328.18% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 57,370 shares of company stock valued at $279,966 in the last three months. 7.54% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Quoin Pharmaceuticals stock. SummitTX Capital L.P. lifted its holdings in Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX – Free Report) by 54.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 100,300 shares of the company’s stock after purchasing an additional 35,505 shares during the period. SummitTX Capital L.P. owned 5.56% of Quoin Pharmaceuticals worth $662,000 at the end of the most recent reporting period. Institutional investors own 8.63% of the company’s stock.

Quoin Pharmaceuticals Company Profile

(Get Free Report)

Quoin Pharmaceuticals, Ltd. is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases. The company is primarily pursuing therapies for conditions with significant unmet medical needs, including rare genetic disorders affecting the skin.

Quoin’s lead program is QRX003, a topical lotion being developed for Netherton syndrome, a rare inherited skin disorder associated with impaired skin-barrier function. The company is also developing QRX004, a topical product candidate intended for recessive dystrophic epidermolysis bullosa, a severe genetic skin disease.